company OVERVIEW

WELCOME TO WINDTREE THERAPEUTICS

Windtree Therapeutics, Inc. is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis.

Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with our lead candidate, istaroxime, being developed as a first in class treatment for cardiogenic shock and acute heart failure.

Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. Included in Windtree’s portfolio is rostafuroxin, a novel drug product targeting the treatment resistant hypertension disease state for patients with certain genetic profiles.